The Novo Nordisk Prize

The Novo Nordisk Prize is an annual award presented to acknowledge exceptional contributions within the fields of medical and health sciences. It is specifically aimed at individuals who have demonstrated outstanding research or innovation that has the potential to advance medical science, particularly in areas related to diabetes, endocrinology, and biopharmaceutical science. The prize is administered by the Novo Nordisk Foundation, an independent Danish enterprise foundation.

Background
Established by the Novo Nordisk Foundation, the prize reflects the Foundation's commitment to support health, scientific, and humanitarian efforts through research. The Foundation holds a controlling interest in the Danish pharmaceutical firm Novo Nordisk.

History of the Novo Nordisk Prize
The prize, originally DKK 50,000 (approx $7,200), was first awarded on 16 February 1963. Since then, the amount awarded has gradually increased. The prize was called the Novo Prize from 1963 until 1989, when it was renamed the Novo Nordisk Prize. Until 2020 the Prize was given for a Danish contribution. In 2020, it has been decided to change the geographical scope of the prize and from 2021 the prize will be awarded for a European contribution.

Award
The Novo Nordisk Prize includes a monetary award, the amount of which can vary from year to year. Alongside the financial component, recipients are also awarded a medal and a diploma in recognition of their contributions. The prize is designed not only to honour exceptional scientific work but also to support the continued research efforts of the recipients.